In the STEPS article “Tapentadol (Nucynta) for Treatment of Pain” (May 1, 2012, page 910), the second sentence of the first paragraph incorrectly states that tapentadol blocks the mu opioid receptor (page 910). The sentence should have read: “It has two mechanisms of action: in addition to acting at the mu opioid receptor, tapentadol blocks norepinephrine uptake, although the clinical relevance of this additional action is not known.” The online version of this article has been corrected.